These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 37686121)

  • 41. Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance?
    Tsirlis TD; Papastratis G; Masselou K; Tsigris C; Papachristodoulou A; Kostakis A; Nikiteas NI
    World J Gastroenterol; 2008 May; 14(17):2691-701. PubMed ID: 18461654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
    Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
    Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
    Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications.
    Campbell KT; Hadley DJ; Kukis DL; Silva EA
    PLoS One; 2017; 12(7):e0181484. PubMed ID: 28723974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues.
    Bardelli M; Leucci E; Schürfeld K; Bellan C; Passiatore G; Rocchigiani M; Bartolommei S; Orlandini M; Zagursky J; Lazzi S; De Falco G; Tosi P; Oliviero S; Leoncini L
    Leuk Lymphoma; 2007 Oct; 48(10):2014-21. PubMed ID: 17917969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo.
    Byzova TV; Goldman CK; Jankau J; Chen J; Cabrera G; Achen MG; Stacker SA; Carnevale KA; Siemionow M; Deitcher SR; DiCorleto PE
    Blood; 2002 Jun; 99(12):4434-42. PubMed ID: 12036873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
    Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
    Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lymphangiogenesis and biological activity ov vascular endothelial growth factor-C].
    Mandriota SJ; Pepper MS
    J Soc Biol; 1999; 193(2):159-63. PubMed ID: 10451350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
    Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C
    Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.
    Bender RJ; Mac Gabhann F
    BMC Syst Biol; 2015 Sep; 9():55. PubMed ID: 26341082
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum vascular endothelial growth factors a, C and d in human breast tumors.
    Gisterek I; Matkowski R; Lacko A; Sedlaczek P; Szewczyk K; Biecek P; Halon A; Staszek U; Szelachowska J; Pudelko M; Bebenek M; Harlozinska-Szmyrka A; Kornafel J
    Pathol Oncol Res; 2010 Sep; 16(3):337-44. PubMed ID: 19821158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D.
    McColl BK; Baldwin ME; Roufail S; Freeman C; Moritz RL; Simpson RJ; Alitalo K; Stacker SA; Achen MG
    J Exp Med; 2003 Sep; 198(6):863-8. PubMed ID: 12963694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
    Peng F; Zhong Y; Liu Y; Zhang Y; Xie Y; Lu Y; Zhang X; Li D
    Int J Oncol; 2017 Dec; 51(6):1920-1928. PubMed ID: 29075785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
    Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
    Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
    Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
    Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of macrophages in inflammatory lymphangiogenesis: Enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation.
    Watari K; Nakao S; Fotovati A; Basaki Y; Hosoi F; Bereczky B; Higuchi R; Miyamoto T; Kuwano M; Ono M
    Biochem Biophys Res Commun; 2008 Dec; 377(3):826-31. PubMed ID: 18951870
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.